150 related articles for article (PubMed ID: 27840303)
1. Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.
Roversi FM; Pericole FV; Machado-Neto JA; da Silva Santos Duarte A; Longhini AL; Corrocher FA; Palodetto B; Ferro KP; Rosa RG; Baratti MO; Verjovski-Almeida S; Traina F; Molinari A; Botta M; Saad ST
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):450-461. PubMed ID: 27840303
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Roversi FM; Bueno MLP; da Silva JAF; Assis-Mendonça GR; Torello CO; Shiraishi RN; Pericole FV; Ferro KP; Duarte ASS; Rego EM; Saad STO
Cancer Immunol Immunother; 2022 Aug; 71(8):1909-1921. PubMed ID: 35039904
[TBL] [Abstract][Full Text] [Related]
3. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
4. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
Saito Y; Yuki H; Kuratani M; Hashizume Y; Takagi S; Honma T; Tanaka A; Shirouzu M; Mikuni J; Handa N; Ogahara I; Sone A; Najima Y; Tomabechi Y; Wakiyama M; Uchida N; Tomizawa-Murasawa M; Kaneko A; Tanaka S; Suzuki N; Kajita H; Aoki Y; Ohara O; Shultz LD; Fukami T; Goto T; Taniguchi S; Yokoyama S; Ishikawa F
Sci Transl Med; 2013 Apr; 5(181):181ra52. PubMed ID: 23596204
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic Cell Kinase (HCK) Is a Player of the Crosstalk Between Hematopoietic Cells and Bone Marrow Niche Through CXCL12/CXCR4 Axis.
Roversi FM; Bueno MLP; Pericole FV; Saad STO
Front Cell Dev Biol; 2021; 9():634044. PubMed ID: 33842460
[TBL] [Abstract][Full Text] [Related]
6. Hck inhibitors as potential therapeutic agents in cancer and HIV infection.
Musumeci F; Schenone S; Brullo C; Desogus A; Botta L; Tintori C
Curr Med Chem; 2015; 22(13):1540-64. PubMed ID: 25666803
[TBL] [Abstract][Full Text] [Related]
7. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
8. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
9. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.
Lopez S; Voisset E; Tisserand JC; Mosca C; Prebet T; Santamaria D; Dubreuil P; De Sepulveda P
Oncotarget; 2016 Aug; 7(32):51163-51173. PubMed ID: 27323399
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative.
Chakraborty MP; Bhattacharyya S; Roy S; Bhattacharya I; Das R; Mukherjee A
J Biol Chem; 2021; 296():100449. PubMed ID: 33617879
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.
Liang H; Zheng QL; Fang P; Zhang J; Zhang T; Liu W; Guo M; Robinson CL; Chen SB; Chen XP; Chen FP; Zeng H
Sci Rep; 2017 Jan; 7():40361. PubMed ID: 28098170
[TBL] [Abstract][Full Text] [Related]
12. Insights on hematopoietic cell kinase: An oncogenic player in human cancer.
Luo S; Du S; Tao M; Cao J; Cheng P
Biomed Pharmacother; 2023 Apr; 160():114339. PubMed ID: 36736283
[TBL] [Abstract][Full Text] [Related]
13. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Parisi S; Finelli C; Fazio A; De Stefano A; Mongiorgi S; Ratti S; Cappellini A; Billi AM; Cocco L; Follo MY; Manzoli L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467674
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells.
Henry MK; Nimbalkar D; Hohl RJ; Quelle FW
Exp Cell Res; 2004 Sep; 299(1):257-66. PubMed ID: 15302592
[TBL] [Abstract][Full Text] [Related]
16. Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor.
Arcasoy MO; Jiang X
Br J Haematol; 2005 Jul; 130(1):121-9. PubMed ID: 15982354
[TBL] [Abstract][Full Text] [Related]
17. Advances in MDS/AML and inositide signalling.
De Stefano A; Marvi MV; Fazio A; McCubrey JA; Suh PG; Ratti S; Ramazzotti G; Manzoli L; Cocco L; Follo MY
Adv Biol Regul; 2023 Jan; 87():100955. PubMed ID: 36706610
[TBL] [Abstract][Full Text] [Related]
18. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Akutagawa J; Huang TQ; Epstein I; Chang T; Quirindongo-Crespo M; Cottonham CL; Dail M; Slusher BS; Friedman LS; Sampath D; Braun BS
Leukemia; 2016 Jun; 30(6):1335-43. PubMed ID: 26965285
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of PI3K and activation of MAPK p38 signaling pathways trigger erythroid alternative splicing switch of 4.1R pre-mRNA in DMSO-induced erythroleukemia cells.
Breig O; Théoleyre-Schaal O; Baklouti F
Cell Signal; 2013 Dec; 25(12):2453-61. PubMed ID: 23993958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
